Welcome to our dedicated page for CV Sciences SEC filings (Ticker: CVSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CV Sciences, Inc. filings document the regulatory disclosures of an OTCQB consumer wellness company selling hemp-derived CBD products and other natural wellness formulations. Form 8-K reports cover financial results, Regulation FD disclosures, non-GAAP reconciliations and material agreements tied to secured promissory notes.
The company’s filings also describe capital-structure matters, including note purchase agreements, amendments to secured debt, conversion features, maturity provisions, security interests in company assets and intellectual property, and common stock issuance mechanics. Proxy materials cover annual meeting procedures, director elections, stockholder voting matters and governance items for the Delaware corporation.
CV Sciences, Inc. (CVSI) reports that ten percent owner Charlie E. Cheever III made a series of open-market or private purchases of common stock between July 16, 2026 and August 7, 2026. Across ten transactions, he purchased a total of 5,740,816 shares at a reported price of $0.02 per share, with all holdings shown as direct ownership and no Rule 10b5-1 trading plan reported.
CV Sciences, Inc. (CVSI) disclosed in a Form 3 that Charlie E. Cheever III is a ten percent owner of the company. As of July 9, 2026, the filing states that securities beneficially owned by Cheever and an associated trust total 26,648,711 shares, representing 10.25% of CV Sciences. This includes 20,026,195 shares of common stock held directly and 881,700 shares held indirectly through a trust for which Cheever serves as trustee with voting and dispositive power.
CV Sciences, Inc. (CVSI) has a large shareholder, Charles E. Cheever III, reporting beneficial ownership of a significant block of its common stock on a Schedule 13G. He reports beneficial ownership of 26,648,711 shares of common stock, representing 13.1% of the class.
Cheever reports sole voting and dispositive power over all 26,648,711 shares and no shared power. This total includes 881,700 shares held by a trust for which he is trustee; he states he has no personal pecuniary interest in those trust shares, but they are included due to his voting and dispositive authority as trustee.
CV Sciences, Inc. reported weaker results for the quarter and six months ended June 30, 2026. Net product sales were $2.99 million in Q2 2026, down 17.5% from $3.62 million, and $6.18 million for the first half, down 14.5%. The decline reflected lower unit volumes driven by restrictive state regulations, out-of-stock issues, and reduced third‑party contract manufacturing revenue, partially offset by contributions from newer products.
Gross margin remained roughly stable at 48.6% in Q2 (50.9% a year earlier). The company recorded a Q2 net loss of $0.78 million and a six‑month net loss of $1.42 million; Adjusted EBITDA was negative in both periods. Cash was only $0.27 million with a small working capital deficit and an accumulated deficit of $89.4 million, and management disclosed substantial doubt about the ability to continue as a going concern, expecting reliance on additional capital and continued cost reductions.
During 2026, a secured promissory note was amended into convertible notes, measured at fair value with a $1.02 million liability at June 30, and 28.9 million shares were issued on conversions in the first half, increasing shares outstanding to 213.1 million (225.8 million by August 11). New U.S. legislation (the 2026 Act) will limit hemp‑derived consumable products to 0.4 mg total THC per container; the company is assessing formulation and compliance changes and states this could materially adversely affect its business.
CV Sciences, Inc. reported second quarter 2026 revenue of $3.0 million, down 17.5% from $3.6 million a year earlier, with a gross margin of 48.6%. The company generated an operating loss of $0.3 million and a net loss of $0.8 million for the quarter.
Operating expenses fell 11.3% to $1.7 million, contributing to positive operating cash flow of $0.1 million for the first six months of 2026. Cash was $0.3 million at June 30, 2026, while total liabilities were $5.0 million and stockholders’ equity was $1.6 million. Adjusted EBITDA was a loss of $0.1 million for the quarter. Management highlighted growth in the +PlusHLTH™ and new product portfolio, which accounted for 44% of net revenue since January 1, 2023.
CV Sciences, Inc. reported results from its 2026 annual stockholder meeting held virtually on June 2, 2026. There were 193,458,420 shares of common stock outstanding as of the April 6, 2026 record date, and 116,234,784 shares, or about 60.1%, were represented by proxy, establishing a quorum.
Stockholders elected three directors to serve until the next annual meeting: Dr. Jamie Corroon, Joseph Dowling, and Bill McCorkle. A proposal to authorize the board to implement a reverse stock split at a ratio between 1-for-10 and 1-for-800 any time before May 30, 2029 was not approved. Stockholders also ratified the selection of Haskell & White LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
CV Sciences, Inc. reported first quarter 2026 results showing lower sales but improved cost control. Revenue was $3.2 million, down from $3.6 million a year earlier and $3.3 million in the fourth quarter 2025, mainly from lower volumes amid restrictive regulations. Gross margin improved to 48.9% from 46.0% a year ago. Operating expenses (excluding a prior-year payroll tax reversal) fell 13.3% to $1.9 million, and the company posted an operating loss of $0.3 million and a net loss of $0.6 million.
Adjusted EBITDA loss narrowed to about $0.1 million from $0.3 million a year earlier, reflecting tighter expense management. Cash was $0.3 million at March 31, 2026, slightly higher than year-end. Management highlighted a completed debt restructuring to strengthen the balance sheet and noted that products launched since January 2023 contributed 43% of net revenue, supported by 45 new product launches.
CV Sciences, Inc. is asking stockholders to approve routine annual matters and a major capital-structure change at its June 2, 2026 virtual meeting. Stockholders will vote on electing three directors, authorizing a reverse stock split between 1-for-10 and 1-for-800 at the Board’s discretion through May 30, 2029, and ratifying Haskell & White LLP as auditor for 2026. The company had 193,458,420 common shares outstanding as of April 6, 2026, with a majority of voting power required for the reverse split and auditor ratification proposals. The reverse split is intended to increase the share price to support a potential Nasdaq Capital Market listing and expand the investor base, while leaving authorized share counts and par value unchanged.
CV Sciences, Inc. entered into an April 9, 2026 amendment with its institutional investor to modify existing secured convertible notes and a newly issued senior secured convertible note. The amendment lowers the fixed conversion price of the amended notes from $0.06 per share to $0.03 per share.
On April 6, 2026, the company issued a Third Note with a principal amount of $99,614.04, which may be converted into common stock. The Third Note’s conversion price is set at $0.03 per share, based on the lesser of that level and the $0.04 closing price before its original issuance date. The Third Note’s maturity was extended to July 6, 2027.